Regeneron Pharmaceuticals Inc

Research Regeneron Pharmaceuticals Inc (REGN) on Bullrun: valuation model: 27.1% undervalued, market cap USD 66.24B, P/E 15.4, dividend yield 0.6%. Explore financials, valuation history, model signals, and stock context.

Key Metrics

• TickerREGN
• ExchangeNASDAQ
• CountryUnited States
• SectorHealthcare
• IndustryBiotechnology
• CurrencyUSD
• Valuation signal27.1% undervalued
• Market capUSD 66.24B
• P/E15.4
• Dividend yield0.6%
• Financial periodFY2025
• RevenueUSD 14.34B
• Revenue growth1.0%
• Net incomeUSD 4.50B
• Free cash flowUSD 4.08B

Valuation Snapshot

Bullrun's latest valuation model marks Regeneron Pharmaceuticals Inc as 27.1% undervalued; latest market cap is USD 66.24B; P/E is 15.4; dividend yield is 0.6%.

About Regeneron Pharmaceuticals Inc

Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines to treat various diseases worldwide. The company develops product candidates to treat eye, allergic and inflammatory, cardiovascular, metabolic, neurological, infectious, and rare diseases; and cancer, hematologic conditions. It also offers EYLEA injections for wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma;

Frequently asked questions

Is Regeneron Pharmaceuticals Inc overvalued or undervalued?

Bullrun's valuation model currently marks Regeneron Pharmaceuticals Inc as 27.1% undervalued.

What is Regeneron Pharmaceuticals Inc's market cap?

Regeneron Pharmaceuticals Inc's market capitalization is USD 66.24B.

What is Regeneron Pharmaceuticals Inc's P/E ratio?

Regeneron Pharmaceuticals Inc's price-to-earnings (P/E) ratio is 15.4.

Does Regeneron Pharmaceuticals Inc pay a dividend?

Regeneron Pharmaceuticals Inc has a dividend yield of 0.6%.

What does Regeneron Pharmaceuticals Inc do?

Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines to treat various diseases worldwide. The company develops product candidates to treat eye, allergic and inflammatory, cardiovascular, metabolic, neurological, infectious, and rare diseases;